San Francisco--Serum BPSA, an antigen enriched in the nodular transition zone tissue in BPH, appears to be a better predictor of clinically significant prostate enlargement than PSA or free PSA. This finding and complementary data, by researchers from the Scott Department of Urology, Baylor College of Medicine, Houston, lay the groundwork for further study that will determine the antigen's potential to distinguish between BPH and prostate cancer.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.